436 related articles for article (PubMed ID: 30301696)
1. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
Pernar CH; Ebot EM; Pettersson A; Graff RE; Giunchi F; Ahearn TU; Gonzalez-Feliciano AG; Markt SC; Wilson KM; Stopsack KH; Gazeeva E; Lis RT; Parmigiani G; Rimm EB; Finn SP; Giovannucci EL; Fiorentino M; Mucci LA
Eur Urol; 2019 Jul; 76(1):33-40. PubMed ID: 30301696
[TBL] [Abstract][Full Text] [Related]
2. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.
Ahearn TU; Pettersson A; Ebot EM; Gerke T; Graff RE; Morais CL; Hicks JL; Wilson KM; Rider JR; Sesso HD; Fiorentino M; Flavin R; Finn S; Giovannucci EL; Loda M; Stampfer MJ; De Marzo AM; Mucci LA; Lotan TL
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26615022
[TBL] [Abstract][Full Text] [Related]
3. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
4. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
[TBL] [Abstract][Full Text] [Related]
5. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.
Pettersson A; Graff RE; Bauer SR; Pitt MJ; Lis RT; Stack EC; Martin NE; Kunz L; Penney KL; Ligon AH; Suppan C; Flavin R; Sesso HD; Rider JR; Sweeney C; Stampfer MJ; Fiorentino M; Kantoff PW; Sanda MG; Giovannucci EL; Ding EL; Loda M; Mucci LA
Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1497-509. PubMed ID: 22736790
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status.
Mancarella C; Casanova-Salas I; Calatrava A; García-Flores M; Garofalo C; Grilli A; Rubio-Briones J; Scotlandi K; López-Guerrero JA
BMC Cancer; 2017 May; 17(1):367. PubMed ID: 28545426
[TBL] [Abstract][Full Text] [Related]
7. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.
Hashim D; Gonzalez-Feliciano AG; Ahearn TU; Pettersson A; Barber L; Pernar CH; Ebot EM; Isikbay M; Finn SP; Giovannucci EL; Lis RT; Loda M; Parmigiani G; Lotan T; Kantoff PW; Mucci LA; Graff RE
Int J Cancer; 2020 May; 146(10):2694-2702. PubMed ID: 31318977
[TBL] [Abstract][Full Text] [Related]
8. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
9. Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status.
Geybels MS; McCloskey KD; Mills IG; Stanford JL
Prostate; 2017 Feb; 77(3):282-290. PubMed ID: 27753122
[TBL] [Abstract][Full Text] [Related]
10. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
[TBL] [Abstract][Full Text] [Related]
11. Height, Obesity, and the Risk of
Graff RE; Ahearn TU; Pettersson A; Ebot EM; Gerke T; Penney KL; Wilson KM; Markt SC; Pernar CH; Gonzalez-Feliciano AG; Song M; Lis RT; Schmidt DR; Vander Heiden MG; Fiorentino M; Giovannucci EL; Loda M; Mucci LA
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):193-200. PubMed ID: 29167279
[No Abstract] [Full Text] [Related]
12. The association of diabetes with risk of prostate cancer defined by clinical and molecular features.
Feng X; Song M; Preston MA; Ma W; Hu Y; Pernar CH; Stopsack KH; Ebot EM; Fu BC; Zhang Y; Li N; Dai M; Liu L; Giovannucci EL; Mucci LA
Br J Cancer; 2020 Aug; 123(4):657-665. PubMed ID: 32467600
[TBL] [Abstract][Full Text] [Related]
13. The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer.
Graff RE; Pettersson A; Lis RT; DuPre N; Jordahl KM; Nuttall E; Rider JR; Fiorentino M; Sesso HD; Kenfield SA; Loda M; Giovannucci EL; Rosner B; Nguyen PL; Sweeney CJ; Mucci LA;
Prostate; 2015 Jun; 75(9):897-906. PubMed ID: 25728532
[TBL] [Abstract][Full Text] [Related]
14. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG.
Pettersson A; Lis RT; Meisner A; Flavin R; Stack EC; Fiorentino M; Finn S; Graff RE; Penney KL; Rider JR; Nuttall EJ; Martin NE; Sesso HD; Pollak M; Stampfer MJ; Kantoff PW; Giovannucci EL; Loda M; Mucci LA
J Natl Cancer Inst; 2013 Dec; 105(24):1881-90. PubMed ID: 24292212
[TBL] [Abstract][Full Text] [Related]
15. Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG.
Graff RE; Judson G; Ahearn TU; Fiorentino M; Loda M; Giovannucci EL; Mucci LA; Pettersson A
Prostate; 2017 May; 77(6):647-653. PubMed ID: 28102015
[TBL] [Abstract][Full Text] [Related]
16. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.
Darnel AD; Lafargue CJ; Vollmer RT; Corcos J; Bismar TA
Cancer Biol Ther; 2009 Jan; 8(2):125-30. PubMed ID: 19029822
[TBL] [Abstract][Full Text] [Related]
17. Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression.
Graff RE; Pettersson A; Lis RT; Ahearn TU; Markt SC; Wilson KM; Rider JR; Fiorentino M; Finn S; Kenfield SA; Loda M; Giovannucci EL; Rosner B; Mucci LA
Am J Clin Nutr; 2016 Mar; 103(3):851-60. PubMed ID: 26817504
[TBL] [Abstract][Full Text] [Related]
18. Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.
Ahearn TU; Peisch S; Pettersson A; Ebot EM; Zhou CK; Graff RE; Sinnott JA; Fazli L; Judson GL; Bismar TA; Rider JR; Gerke T; Chan JM; Fiorentino M; Flavin R; Sesso HD; Finn S; Giovannucci EL; Gleave M; Loda M; Li Z; Pollak M; Mucci LA;
Carcinogenesis; 2018 Dec; 39(12):1431-1437. PubMed ID: 30165429
[TBL] [Abstract][Full Text] [Related]
19. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
[TBL] [Abstract][Full Text] [Related]
20. Physical Activity and Survival After Prostate Cancer.
Friedenreich CM; Wang Q; Neilson HK; Kopciuk KA; McGregor SE; Courneya KS
Eur Urol; 2016 Oct; 70(4):576-585. PubMed ID: 26774959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
